Relationship Between Exposure to Phenols and Pregnancy Outcomes After Embryo Transfer

July 17, 2025 updated by: keqin liu

The goal of this observational study is to explore the association between phenol exposure and pregnancy outcome after embryo transfer. The main question it aims to answer [is/are]:

Whether exposure to phenols is associated with adverse pregnancy outcomes in pregnant women undergoing assisted reproductive technology?

Study Overview

Status

Completed

Conditions

Detailed Description

First of all, paper questionnaires were used in this study, including general information questionnaire, health effect questionnaire, health survey summary form, and dietary assessment questionnaire. Secondly, obtain the relevant information of the medical record system, including: assisted reproduction protocol, IVF examination results, B-ultrasound examination results, laboratory test indicators, pregnancy outcome information and newborn information. Finally, urine samples were detected using a high performance liquid chromatography mass spectrometer.

Study Type

Observational

Enrollment (Actual)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • WuHan, Hubei, China, 430030
        • Reproductive center，tongji hospital，huazhong university of science and technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Pregnant women undergoing assisted reproductive technology in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China from 2024 to 2025

Description

Inclusion Criteria:

  1. Chinese citizens over the age of 20;
  2. IVF/ICSI assisted reproductive treatment in our center;
  3. Complete clinical data, reproductive outcomes and questionnaire data of both sexes;
  4. Knowing about this research and voluntarily accepting this research;

Exclusion Criteria:

  1. The patient receives sperm or egg donation treatment;
  2. The patient gave up the egg collection operation due to various reasons, and the cycle was canceled;
  3. The patient abandons treatment before achieving clinical pregnancy, but the fertile frozen embryo is not transferred;
  4. There are contraindications to pregnancy, such as serious liver and kidney diseases, malignant tumors, serious mental diseases, uncorrected coagulation function abnormalities or endocrine indicators abnormalities;
  5. Incomplete or missing clinical data or follow-up data;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Pregnant women undergoing assisted reproductive technology in Tongji Hospital, Wuhan City, Hubei Pro
  1. Chinese citizens over the age of 20;
  2. IVF/ICSI assisted reproductive treatment in our center;
  3. Complete clinical data, reproductive outcomes and questionnaire data of both sexes;
  4. Knowing about this research and voluntarily accepting this research;

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of clinical pregnancy patients
Time Frame: From the date of randomization until the termination of pregnancy
Rate of biochemical pregnancy, clinical pregnancy and post-natal patients
From the date of randomization until the termination of pregnancy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of the health newborn
Time Frame: From the date of randomization until the termination of pregnancy
gestational age/preterm birth, physical health at birth, the incidence of systemic abnormalities or diseases, and other health outcomes
From the date of randomization until the termination of pregnancy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

keqin liu

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2025

Primary Completion (Actual)

July 1, 2025

Study Completion (Actual)

July 1, 2025

Study Registration Dates

First Submitted

January 6, 2025

First Submitted That Met QC Criteria

January 6, 2025

First Posted (Actual)

January 9, 2025

Study Record Updates

Last Update Posted (Actual)

July 18, 2025

Last Update Submitted That Met QC Criteria

July 17, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • liukeqin0208

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Embryo Transfer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe